Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF(V600E) colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Jun, Chen, Jonathan H., Chao, Sherry X., Pelka, Karin, Giannakis, Marios, Hess, Julian, Burke, Kelly, Jorgji, Vjola, Sindurakar, Princy, Braverman, Jonathan, Mehta, Arnav, Oka, Tomonori, Huang, Mei, Lieb, David, Spurrell, Maxwell, Allen, Jill N., Abrams, Thomas A., Clark, Jeffrey W., Enzinger, Andrea C., Enzinger, Peter C., Klempner, Samuel J., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ryan, David P., Yurgelun, Matthew B., Kanter, Katie, Van Seventer, Emily E., Baiev, Islam, Chi, Gary, Jarnagin, Joy, Bradford, William B., Wong, Edmond, Michel, Alexa G., Fetter, Isobel J., Siravegna, Giulia, Gemma, Angelo J., Sharpe, Arlene, Demehri, Shadmehr, Leary, Rebecca, Campbell, Catarina D., Yilmaz, Omer, Getz, Gad A., Parikh, Aparna R., Hacohen, Nir, Corcoran, Ryan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941044/
https://www.ncbi.nlm.nih.gov/pubmed/36702949
http://dx.doi.org/10.1038/s41591-022-02181-8

Ejemplares similares

Ejemplares similares